A Phase II Study of IRD (Ixazomib, Lenalidomide, & Dexamethasone) for Consolidation Therapy Post Autologous Stem Cell Transplantation Followed by Maintenance Ixazomib or Lenalidomide for Multiple Myeloma
Phase of Trial: Phase II
Latest Information Update: 20 Nov 2017
At a glance
- Drugs Ixazomib (Primary) ; Dexamethasone; Lenalidomide
- Indications Multiple myeloma
- Focus Therapeutic Use
- 01 Jun 2017 Planned number of patients changed from 130 to 240.
- 26 Jan 2017 Planned End Date changed from 1 Apr 2021 to 31 Oct 2022.
- 26 Jan 2017 Planned primary completion date changed from 1 Jun 2017 to 31 Oct 2018.